Treatment of Pseudomonas Bacteremia in Ventilated Patients

Introduction to Treatment Guidelines

The European Respiratory Society recommends that for a ventilated patient with Pseudomonas bacteremia, levofloxacin should not be used as monotherapy but rather as part of dual antipseudomonal combination therapy with a β-lactam agent such as cefepime, piperacillin-tazobactam, or a carbapenem 1, 2

A ventilated patient with Pseudomonas bacteremia meets criteria for high-risk treatment based on the need for ventilatory support, indicating severe pneumonia or respiratory failure, and the presence of bacteremia suggesting systemic infection with potential for septic shock 1, 2

Dual antipseudomonal coverage is mandatory and should include an antipseudomonal β-lactam, such as cefepime 2g IV q8h, piperacillin-tazobactam 4.5g IV q6h, meropenem or imipenem, or ceftazidime 2g IV q8h, plus a second antipseudomonal agent, such as ciprofloxacin 400mg IV q8h or an aminoglycoside 1, 2
The American Thoracic Society and the Infectious Diseases Society of America recommend that the choice of antibiotic regimen should be based on local antibiogram results, with consideration of the patient's renal function and potential for nephrotoxicity 1, 2

Combination therapy is essential to prevent the emergence of resistance, as Pseudomonas aeruginosa rapidly develops resistance to fluoroquinolone monotherapy, and to provide broader coverage against potential co-pathogens 1, 2
The European Respiratory Society recommends that combination therapy should be continued for 3-5 days, then considered for de-escalation to monotherapy based on culture results and clinical response 1

Local antibiogram is paramount, and if the institution's Pseudomonas isolates show <90% susceptibility to levofloxacin, an aminoglycoside should be considered instead 1, 3
The Infectious Diseases Society of America recommends that MRSA coverage should be added to the regimen if >25% of S. aureus isolates in the ICU are MRSA 1, 2